Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CASI and BioInvent Start China Trial of FcγRIIB Inhibitor for NHL

publication date: Sep 7, 2022

CASI Pharma and Stockhom’s BioInvent have dosed the first patient in a China Phase I trial of their novel cancer immunotherapy. The trial will test BI-1206, a first-in-class fully human mAb targeting FcγRIIB, in combination with rituximab for relapsed/refractory Non-Hodgkin's Lymphoma (NHL). In 2020, CASI acquired China rights to the candidate from BioInvent in a $95 million deal. BioVent says FcyRIIB is a single inhibitory antibody checkpoint that unlocks anti-cancer immunity. CASI is a Maryland company that brings novel drugs to China. More details....

Stock Symbols: (NSDQ: CASI) (NSDQ: Stockholm: BINV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022